Leading innovation to enhance industrial production of gene therapy at scale
Yposkesi is at the forefront of Innovation. As a spin off from Genethon, our fully dedicated Innovation team is working jointly with Genethon’s Innovation team, our objective is to adapt ourselves to the evolving needs of our clients and continuously deliver on all commitments as a long term, sustainable and competitive supplier.
The industrialization of the manufacturing processes of viral vectors is certainly one of the key challenges that the bioproduction world is facing today. Processes are not delivering high yield, and not efficient enough in many cases to answer market needs.
We are working on increasing process productivity and optimizing manufacturing costs, through a broad range of innovative technologies. For instance, we have actually developed a high yield AAV platform using the gold standard triple transfection process, with a new transfecting agent and a high producer clone (proprietary). For lentiviral vectors, we have a patented large scale suspension process (> 50 L), using a new transfectant.